{{copyedit|time=2019-01-09T09:21:23+00:00}}
{{medical}}
{{noteTA
|T=zh-hant:鞘内; zh-hans:鞘内;
|G1=Kavalan language
}}
{{Infobox anatomy
| Name        = 蛛網膜下腔
| Latin       = Spatium subarachnoideum, <br>cavum subarachnoideale
| Image       = 1316 Meningeal LayersN.jpg
| Caption     = Diagrammatic representation of a section across the top of the skull, showing the membranes of the brain, etc. ("Subarachnoid cavity" visible at left.)
| Image2      = Gray770-en.svg
| Caption2    = Diagrammatic transverse section of the medulla spinalis and its membranes. (Subarachnoid cavity colored blue.)
| System      = 
<!--
| GraySubject = 193
| GrayPage    = 876
| MeshName    = Subarachnoid+Space
| MeshNumber  = A08.186.566.166.686
| DorlandsPre = s_16
| DorlandsSuf = 12746651
-->
}}

'''鞘內'''({{lang|en|intrathecal}}、<{{lang|en|intra- + theca}}、{{lang|en|IT}}、"{{lang|en|within a sheath}}">、脊髓內、'''鞘内注射'''、脊髓腔內注射)指某些東西"發生在"或"引入到"鞘內部(一般而言指[[脑|脑]]或[[脊髓|脊髓]][[蛛網膜|蛛網膜]](arachnoid mater)、在其下是[[蛛網膜下腔|蛛網膜下腔]]<subarachnoid space>)的[[解剖空間|解剖空間]](Spatium)或[[潛在空間|潛在空間]](potential space)之情狀。<ref>{{cite web|title=Route of Administration|url=http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071667.htm|work=Data Standards Manual|publisher=Food and Drug Administration|accessdate=11 March 2011|archive-date=2019-02-08|archive-url=https://web.archive.org/web/20190208125312/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071667.htm|dead-url=no}}</ref> 例如："鞘內免疫球蛋白"(intrathecal immunoglobulin)，以及"鞘內注射"(intrathecal injection、通常簡稱為"鞘內"<an intrathecal>)等。"鞘內免疫球蛋白"的製造是產生在脊髓的抗體裡。<ref>{{cite journal | last1 = Meinl | first1 = E | last2 = Krumbholz | first2 = M | last3 = Derfuss | first3 = T | last4 = Junker | first4 = A | last5 = Hohlfeld | first5 = R | title = Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis | journal = Journal of the neurological sciences | volume = 274 | issue = 1–2 | pages = 42–4 | year = 2008 | pmid = 18715571 | doi = 10.1016/j.jns.2008.06.032 }}</ref> 而"鞘內注射"是讓"藥物"通過[[给药途径|给药途径]][[注射|注射]]到椎管，更具體地說是進入"蛛網膜下腔"以到達[[腦脊液|腦脊液]](CSF)，且用於[[脊髓麻醉|脊髓麻醉]](Spinal anaesthesia)、[[化学疗法|化学疗法]]，或[[疼痛管理|疼痛管理]](Pain management)等應用方面。這條"鞘內注射"的"給藥途徑"也可用於引入"某些藥物"來對抗某些感染，特別是"後神經外科藥物"(post-neurosurgical)。這種"後神經外科藥物"需要以此"鞘內注射的給藥途徑"來處理以避免[[血腦屏障|血腦屏障]]。不同於鞘內注射、[[口服|口服]](Oral administration (per os))亦給予"相同的藥物"且一定會傳入血流裡，不過可能無法對大腦進行傳遞。鞘內注射藥物的處方必須由專門的[[藥劑師|藥劑師]]或技術人員處理，藥物不能包含任何的[[防腐劑|防腐劑]]或其他可能有害的"非活性"(inactive)成分，不過有時在標準程序注射藥物製劑時會發現這些情況。

==鎮痛藥鞘內注射==
{{main|椎管內麻醉}}

*通常的方法是給予單一24小時的鎮痛劑量(以阿片類藥物進行[[局部麻醉药|局部麻醉药]])。
*注意會引起"遲發性呼吸抑制"(late onset respiratory depression)的症狀。
*嚴重的[[癢|瘙癢]]與[[尿瀦留|尿瀦留]]可能會限制使用"鞘內[[嗎啡|嗎啡]]"。

==參見==
* [[硬膜囊|硬膜囊]](Thecal sac)
* [[囊|囊]](Theca)
* [[椎管內麻醉歷史|椎管內麻醉歷史]](History of neuraxial anesthesia)
*[[神經科學期刊|神經科學期刊]](The Journal of Neuroscience/神经科学杂志)

==註釋==
{{reflist|1}}

{{Dosage forms|state=show}}

[[Category:治療|Category:治療]]
[[Category:给药途径|Category:给药途径]]
[[Category:剂型|Category:剂型]]